Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) is expected to release its earnings data before the market opens on Thursday, March 13th. Analysts expect Akebia Therapeutics to post earnings of ($0.05) per share and revenue of $37.36 million for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

Akebia Therapeutics Trading Down 1.0 %

Shares of AKBA stock traded down $0.02 during trading on Friday, hitting $1.90. The company's stock had a trading volume of 2,284,590 shares, compared to its average volume of 2,239,886. The company has a market cap of $414.54 million, a PE ratio of -8.26 and a beta of 0.94. The business has a fifty day moving average of $2.02 and a 200-day moving average of $1.77. Akebia Therapeutics has a 52 week low of $0.80 and a 52 week high of $2.48.

Insider Activity at Akebia Therapeutics

In other news, CAO Richard C. Malabre sold 30,202 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $63,424.20. Following the sale, the chief accounting officer now directly owns 280,248 shares in the company, valued at $588,520.80. This represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Steven Keith Burke sold 50,506 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $2.10, for a total value of $106,062.60. Following the sale, the senior vice president now owns 816,234 shares in the company, valued at approximately $1,714,091.40. This represents a 5.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 280,579 shares of company stock worth $589,216. Insiders own 4.10% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on AKBA. HC Wainwright reaffirmed a "buy" rating and issued a $7.50 target price on shares of Akebia Therapeutics in a report on Thursday, January 23rd. StockNews.com downgraded Akebia Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.